INEP medical s.r.o.

At INEP medical s.r.o. in Prague, a major focus is on major depressive disorder and treatment-resistant depression, with studies also addressing anhedonia and relapse prevention. These trials are designed to test new treatment options, improve symptom control, and better understand long-term benefit in people who have not responded well to standard antidepressants.

• Major depressive disorder and treatment-resistant depression
• Anhedonia and anxious distress in depression
• Testing new adjunctive and standalone therapies for depressive symptoms
• Evaluating relapse prevention and long-term safety

This research reflects a strong emphasis on finding more effective and durable approaches for complex depressive illness.

The site is actively studying Alzheimer’s disease across several related problems, including psychosis, agitation, and cognitive impairment. The goal of these trials is to assess whether new therapies can reduce behavioral symptoms, support thinking and functioning, and improve care for people living with dementia-related complications.

• Alzheimer’s disease and mild to moderate Alzheimer’s disease
• Agitation and psychosis associated with Alzheimer’s disease
• Cognitive and global functioning in dementia
• Testing treatments aimed at symptom relief and better daily functioning

This area shows a clear interest in both behavioral and cognitive aspects of neurodegenerative disease.

Another important research stream at INEP medical s.r.o. covers generalized anxiety disorder, schizophrenia, and cognitive disorder. These studies are evaluating potential new ways to ease anxiety symptoms, improve cognition, and address persistent challenges linked to psychotic disorders and related cognitive problems.

• Generalized anxiety disorder
• Schizophrenia and cognitive impairment associated with schizophrenia
• Cognitive disorder and related mental functioning issues
• Assessing symptom improvement and treatment tolerability

The work in this field aims to broaden options for patients with difficult-to-treat psychiatric and cognitive conditions.

The site also conducts trials in nervous system diseases and musculoskeletal diseases, including migraine, refractory partial onset epilepsy, tardive dyskinesia, and chronic low back pain. These studies are focused on improving prevention, reducing attack frequency or symptom burden, and evaluating whether new therapies can offer better relief for people with ongoing neurological or pain-related conditions.

• Migraine prevention and acute migraine treatment
• Drug-resistant focal onset seizures and epilepsy control
• Tardive dyskinesia symptom reduction
• Chronic non-specific low back pain and pain relief

This portfolio highlights a broader interest in both neurological symptom management and persistent pain conditions.